No abstract available
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / pathology
-
Aged
-
Androgen Antagonists / adverse effects
-
Androgen Antagonists / therapeutic use*
-
Antihypertensive Agents / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Blood Pressure / drug effects
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / prevention & control*
-
Dyslipidemias / blood
-
Dyslipidemias / complications
-
Dyslipidemias / diagnosis
-
Dyslipidemias / therapy*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hypertension / complications
-
Hypertension / diagnosis
-
Hypertension / physiopathology
-
Hypertension / therapy*
-
Lipids / blood
-
Male
-
Neoplasm Grading
-
Oligopeptides / adverse effects
-
Oligopeptides / therapeutic use*
-
Platelet Aggregation Inhibitors / therapeutic use
-
Prostatic Neoplasms / complications
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / pathology
-
Risk Factors
-
Risk Reduction Behavior
-
Smoking Cessation
-
Treatment Outcome
Substances
-
Androgen Antagonists
-
Antihypertensive Agents
-
Antineoplastic Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Lipids
-
Oligopeptides
-
Platelet Aggregation Inhibitors
-
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide